home | publications


1. Benign Prostatic Hyperplasia: New Concepts for the Millennium.
Zorn B, Bauer JJ, and Moul JW:
The American Journal of Managed Care, 5: 911-922, 1999.

2. Expression Profile of an Androgen Regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.
Xu L, Srikantan V, Sesterhenn IA, Augustus M, Dean R, Moul JW, Carter KC, and Srivastava S:
J Urol, 3:47-70, 1999.

3. p53 and BCL-2 Immunohistochemistry in Pretreatment Prostate Needle Biopsies to Predict Recurrence of Prostate Cancer after Radical Prostatectomy.
Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava S, and Moul JW:
J Urol, 162:2040-2045, 1999.

4. Molecular progression of prostate cancer.
Srivastava S, and Moul JW:
Advances in Oncobiology. Jai Press Inc. 3:155-187, 1999.

5. Chromosome 6q alterations in human prostate cancers.
Srikantan V, Sesterhenn IA, Davis L, Hankins GR, Avallone FA, Livesey JR, Connelly R, Mostofi FK, McLeod DG, Moul JW, Chandrasekharappa SC and Srivastava S:
Int. J. Cancer, 84:331-335, 1999.

6. Prostate-Specific Antigen to Predict Outcome of External-Beam Radiation for Prostate Cancer: Walter Reed Army Medical Center Experience: 1988-1995.
Preston DM, Bauer JJ, Connelly RR, Leifer ES, Halligan J, Sawyer T, McLeod DG, Moul JW:
Urology, 53: 131-138, 1999.

7. Update of Clinical and Basic Science Research on Prostate Cancer from the Department of Defense Center for Prostate Disease Research (DOD-CPDR).
Moul JW:
Prostate Cancer and Prostatic Diseases 2(suppl. 3): S22, 1999.

8. The Foster/Nichols Article Reviewed (Clinical Stage 1 NSGCT).
Moul JW:
Oncology, 13(12): 1700-1703, 1999.

9. Rising PSA After Local Therapy Failure: Immediate vs Deferred Treatment.
Moul JW:
Oncology, 13(7): 985-999, 1999.

10. Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy.
Moul JW:
European Urology, 35: 399-407, 1999.

11. A PSA cutoff on 4 is too high for many men.
Moul JW:
Contemporary Urology 15-33, July, 1999.

12. Prostate Cancer in the Late 1990's: Hormone Refractory Disease Options.
Moul JW, Lipo DR:
Urologic Nursing, 19(2):125-131, 1999.

13. Racial Differences in Tumor Volume and Prostate Specific Antigen among Radical Prostatectomy Patients.
Moul JW, Connelly RR, Mooneyhan RM, Zhang W, Sesterhenn IA, Mostofi FK, and McLeod DG:
The Journal of Urology, 162: 394-397, 1999.

14. Blinded Evaluation of Reverse-Transcriptase Chain Reaction (RT-PCR) Prostate Specific Antigen (PSA) Peripheral Blood Assay for Molecular Staging of Prostate Cancer.
Gao C, Maheshwari S, Dean RC, Tatum L, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW:
Urology, 53:714-721, 1999.

15. Detection of Circulating PSA-expressing Prostatic Cells in the Bone Marrow of Radical Prostatectomy Patients by Sensitive Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).
Gao C, Dean RC, Pinto A, Mooneyhan R, Connelly RR, McLeod DG, Srivastava S, Moul JW:
J Urol, 161: 1076-1076, 1999.

16. 3-D Computer Simulated Prostate Models Lateral Prostate Biopsies Increase the Detection Rate of Prostate Cancer.
Bauer JJ, Zeng J, Weir J, Zhang W, Sesterhenn IA, Connelly RR, Mun SK, Moul JW:
Urology, 53:961-967, 1999.